{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-002742","form_type":"8-K","ticker":"ELUT","cik":"0001708527","company_name":"ELUTIA INC.","filed_at":"2026-01-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.960448+00:00","generated_at":"2026-05-16T10:53:59.399671+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Elutia reports preliminary Q4 2025 revenue $3.3M (+16% YoY); eliminates $26.9M debt","bullets":["Preliminary Q4 net sales ~$3.3M, up 16% YoY, excluding divested BioEnvelope business.","Repaid full $26.9M debt to SWK Holdings, significantly cutting interest expense.","Cash on hand $36.3M; $8M escrow from BioEnvelope divestiture expected in 2026.","Plans FDA filing for NXT-41 base matrix in H1 2026, clearance H2 2026; NXT-41x clearance H1 2027.","CEO cites $88M EluPro divestiture to Boston Scientific as transformational, funding NXT-41x."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-002742","json":"https://secwatch.observer/filing/0001104659-26-002742.json","markdown":"https://secwatch.observer/filing/0001104659-26-002742.md","text":"https://secwatch.observer/filing/0001104659-26-002742.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1708527/000110465926002742/0001104659-26-002742-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1708527/000110465926002742/elut-20260112x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T10:53:59.399671+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}